SCHEMBL5651688

SCHEMBL5651688

CCOC(=O)C(Cc1ccccc1)C(N)(O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.51
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
EPHX2 P34913 1/20 0.43
PPARG P37231 1/20 0.43
TP53 P04637 1/20 0.43
PIN1 Q13526 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
KMT2A Q03164 1/20 0.42
HPRT1 P00492 1/20 0.42
LMNA P02545 2/20 0.42
SRR Q9GZT4 1/20 0.41
PPID Q08752 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651363 1.00 MMP8 (0.51) MMP8ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL5650006 0.88 MMP8 (0.52) MMP8ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL5653528 0.88 MMP8 (0.52) MMP8ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL10420967 0.86 LTA4H (0.47) ALDH1A1SMN1; SMN2PKML3MBTL1MEN1
SCHEMBL8442322 0.86 LTA4H (0.47) ALDH1A1SMN1; SMN2PKML3MBTL1MEN1
SCHEMBL6708542 0.85 MMP8 (0.49) MMP8ALDH1A1KDM4ESMN1; SMN2PKM
SCHEMBL5650826 0.84 MMP1 (0.47) SMN1; SMN2MAPTSRRPOLB
SCHEMBL27439561 0.84 MMP1 (0.47) SMN1; SMN2MAPTSRRPOLB
SCHEMBL5652628 0.84 MMP1 (0.47) SMN1; SMN2MAPTSRRPOLB
SCHEMBL14770008 0.83 MMP8 (0.55) MMP8ALDH1A1SMN1; SMN2MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307184-B2 Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds KANEKA CORPORATION (JP) 2007-12-11 US disclosed
US-20040181074-A1 Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound KANEKA CORPORATION (JP) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181074-A1 Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound HNMT, PNMT, HRH4 MMP8 4042/4885ALDH1A1 1062/4885KDM4E 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.